Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:November 12, 2018
End Date:August 24, 2022
Contact:Novartis Pharmaceuticals
Email:novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma

This is a multi-center, phase II study to determine the efficacy and safety of
tisagenlecleucel in adult patients with relapsed or refractory FL.


Inclusion Criteria:

- Refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A)

- Radiographically measurable disease at screening

Exclusion Criteria:

- Evidence of histologic transformation

- Follicular Lymphoma Grade 3B

- Prior anti-CD19 therapy

- Prior gene therapy

- Prior adoptive T cell therapy

- Prior allogeneic hematopoietic stem cell transplant

- Active CNS involvement by malignancy
We found this trial at
6
sites
Chicago, Illinois 60637
Principal Investigator: Peter Riedell
Phone: 773-834-8980
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1150 East Medical Center Drive
Ann Arbor, Michigan 48109
Principal Investigator: Monalisa Ghosh
Phone: 734-615-4762
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Leslie Popplewell
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Herston, Queensland
?
mi
from
Herston,
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Nathan Fowler
Phone: 713-792-2171
?
mi
from
Houston, TX
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Stephen Schuster
Phone: 215-615-6721
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials